Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

59.86 +0.51 (+0.86%)
Streaming Delayed Price Updated: 12:37 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
35 36 Next >
News headline image
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
News headline image
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
From Genentech
Via Business Wire
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
Via Benzinga
News headline image
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
News headline image
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
From Genentech
Via Business Wire
News headline image
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
News headline image
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
News headline image
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? ↗
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients... 
Via Benzinga
News headline image
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
News headline image
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
News headline image
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point? ↗
Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have... 
Via Benzinga
News headline image
Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million ↗
Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase... 
Via Talk Markets
News headline image
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
News headline image
3 Top Stocks That Could Still Rocket Higher in 2024 ↗
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
News headline image
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential ↗
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... 
Via Benzinga
News headline image
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
From Genentech
Via Business Wire
News headline image
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points ↗
NFLX is among four stocks on the list that's actionable now. 
Via Investor's Business Daily
News headline image
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows ↗
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral. 
Via Benzinga
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
From Genentech
Via Business Wire
News headline image
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
News headline image
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections ↗
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease. 
Via Benzinga
News headline image
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily
News headline image
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 ↗
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track. 
Via The Motley Fool
News headline image
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
From Genentech
Via Business Wire
News headline image
Why Roche Holdings Stock Withered on Wednesday ↗
The company had a dispiriting update to offer about an investigational drug. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.